Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
- Arizona Center for Cancer Care-Peoria — Peoria, Arizona
+ 276 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Locations: - Investigative Site US058 — Birmingham, Alabama
- Investigative Site US016 — Anchorage, Alaska
- Investigative Site US026 — Chandler, Arizona
+ 63 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Locations: - Local Institution - 0142 — Phoenix, Arizona
- Local Institution - 0365 — Tucson, Arizona
- Highlands Oncology Group — Springdale, Arkansas
+ 46 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Locations: - City of Hope (Adults and Pediatrics) — Duarte, California
- University of California San Diego Moores Cancer Center (Adults only) — La Jolla, California
- Loma Linda University Medical Center (Adults only) — Loma Linda, California
+ 37 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Locations: - Exelixis Clinical Site #43 — Birmingham, Alabama
- Exelixis Clinical Site #36 — Phoenix, Arizona
- Exelixis Clinical Site #42 — Tucson, Arizona
+ 36 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Locations: - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
- The University of Alabama at Birmingham — Birmingham, Alabama
- Central Arkansas Radiation Therapy Institute, dba CARTI — Bryant, Arkansas
+ 31 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…
Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Locations: - Genesis Cancer and Blood Institute (SCRI) — Hot Springs, Arkansas
- Providence Medical Foundation — Fullerton, California
- Yale Cancer Center — New Haven, Connecticut
+ 11 more sites in the U.S.
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Locations: - Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton — Fullerton, California
- Baptist MD Anderson Cancer Institute — Jacksonville, Florida
- Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care — Edgewood, Kentucky
+ 9 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Locations: - Investigative Site — Chicago, Illinois
- Investigative Site — Bethesda, Maryland
- Investigative Site — Boston, Massachusetts
+ 5 more sites in the U.S.
Phase 3 Recruiting Industry
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Locations: - Ventura Clinical Trials — Ventura, California
- Clavis Medical, LLC — Miami Lakes, Florida
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
Phase 3 Recruiting Industry
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first li…
Sponsor: Eleison Pharmaceuticals LLC.
NCT ID: NCT01954992
Locations: - Innovative Clinical Research Institute — Whittier, California
- Moffitt Cancer Center — Tampa, Florida
- Gabrail Cancer Center Research — Canton, Ohio